Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

Summary

In a 52‑week, double‑blind phase 2 trial (n=592), once‑monthly maridebart cafraglutide achieved −12.3% to −16.2% weight loss in people with obesity and −8.4% to −12.3% in those with obesity and type 2 diabetes, versus minimal loss with placebo. HbA1c fell by ~1.2–1.6 percentage points in participants with diabetes. Gastrointestinal events were common but manageable and less frequent with dose‑escalation regimens.

Key Findings

• Weight loss at week 52 was −12.3% to −16.2% with maridebart vs −2.5% with placebo in people with obesity.
• In obesity with T2D, weight loss was −8.4% to −12.3% and HbA1c decreased by −1.2 to −1.6 percentage points vs +0.1 with placebo.
• GI adverse events were common; dose-escalation reduced their frequency, and no unexpected safety signals emerged.

Clinical Implications

If confirmed in phase 3 and outcomes trials, monthly multiagonism could expand options for patients requiring potent weight loss with reduced injection burden, including those with T2D. Monitoring for gastrointestinal tolerability and individualized dose-escalation strategies will be important.

Limitations

• Phase 2 trial without head-to-head comparison versus current standard anti-obesity agents (e.g., semaglutide)
• Lacks cardiovascular outcomes and longer-term safety data; GI tolerability may limit adherence

Future Directions

Confirm efficacy, safety, and cardiometabolic outcomes in phase 3; evaluate adherence and quality-of-life with monthly dosing; compare head-to-head with current GLP-1/GIP agonists.